Midatech Appoints Dr Jim Phillips as Chief Executive Officer
News Sep 17, 2013
Dr Philips (50) has over 25 years of senior management and Board level experience in public and private companies across Europe, the US and Australia. During this time he has accumulated considerable expertise in M&A and licensing deal origination and execution, which he now brings to the role of CEO of Midatech.
Dr Phillips joins Midatech from Healthcare Brands International Ltd (HBI), the UK consumer healthcare company, where he has been CEO since 2010. Between 2007 and 2012 he served as Non-executive Chairman of Prosonix Ltd, a specialty pharmaceutical company developing respiratory medicines using an innovative particle-engineering technology and approach.
Before joining HBI, Dr Phillips was CEO of Vantia Ltd., a pharmaceutical company developing novel, small molecule drugs. Prior to that he founded and served as CEO of Talisker Pharma until its acquisition by EUSA in 2006, upon which he became President of EUSA Pharma Europe and an Executive Board Member EUSA Pharma Inc. Dr Phillips has also held senior roles in drug and business development in Novartis and Johnson & Johnson.
Commenting on the appointment, Professor Thomas Rademacher, Chairman of Midatech said: “I am very pleased to welcome Jim to the Company as our new CEO. I have no doubt his senior management and commercial experience within the Biotechnology sector will help us sign the partnership deals and raise the funds we need to deliver the significant potential of our unique gold-nanoparticle technology.”
Dr Philips added: “I am excited to have joined Midatech at this crucial stage as it accelerates the development and commercialisation of its novel gold nanoparticle technology. With its potential to greatly improve the delivery of important drugs for the treatment of diabetes and various cancer types, as well as uses in medical diagnostics and imaging, I am confident that Midatech will generate significant growth and value over the next several years.”
Innovative ALS Therapy Startup Wins Golden Ticket Funding From AmgenNews
Amgen and LabCentral have announced that Kernal Biologics Inc. and QurAlis have won the Amgen Golden Ticket at LabCentral.READ MORE
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE